期刊文献+

酶放大免疫分析法与二维高效液相色谱法监测万古霉素血药浓度的比较 被引量:6

Comparison of EMIT and 2D-HPLC-UV in the Quantification of Vancomycin in Human Plasma
下载PDF
导出
摘要 万古霉素血药浓度个体差异较大,故临床需监测其血药浓度。本文分别建立酶放大免疫分析法(EMIT)、二维高效液相色谱法(2D-HPLC-UV)测定万古霉素血药浓度,2种方法的线性、准确度和精密度均符合生物样品检定要求。60份静脉滴注万古霉素患者的血浆样品测定结果显示,两种方法无统计学差异,且相关性好,回归方程为Y2D-HPLC-UV=0.9670×XEMIT-0.7029,Bland-Altman分析显示两种方法一致性良好。两种方法均可有效且可靠地监测万古霉素血药浓度,临床上应综合考虑监测目的、实验室条件和人员配置等,选择合适的测定方法。 There exist great individual differences in the concentration of vancomycin, so it is necessary to monitor its concentration in clinic. An enzyme multiplied immunoassay technique (EMIT) and a two-di- mensional liquid chromatography coupled with uhraviolet detection method (2D-HPLC-UV) were established to measure the concentration of vancomycin in human plasma. The linear range, accuracy and precision of the two methods satisfied the requirements for bioanalysis. Sixty plasma samples from patients intravenously infused with vancomycin were detected by EMIT and 2D-HPLC-UV, respectively. There were no significant differences in the plasma concentrations of vancomycin detected by EMIT and 2D-HPLC-UV. A good cor- relation was obtained between the two methods. The regression equation was Y2D-HPLC-UV=0.9670XXEMTT-0.7029. Bland-Airman plots analysis showed the two methods were consistent. Both EMIT and 2D-HPLC-UV were effective and reliable in the quantification of vancomycin. The monitoring purpose, laboratory conditions and staffing should be taken into consideration when a method was chosen for monitoring the concentration of vancomycin.
出处 《药学与临床研究》 2018年第1期26-29,共4页 Pharmaceutical and Clinical Research
基金 中央高校基本科研业务费专项资金(021414380294)
关键词 万古霉素 酶放大免疫分析法 二维高效液相色谱法 浓度 Vancomycin EMIT 2D-HPLC-UV Concentration
  • 相关文献

参考文献4

二级参考文献25

  • 1吴建浓,施敏凤,王灵聪,叶雪惠.万古霉素治疗葡萄球菌肺炎的疗效与肾毒性评价[J].中国新药与临床杂志,2005,24(3):245-247. 被引量:7
  • 2肖力,任斌,陈小陆.荧光偏振法测定去甲万古霉素血药浓度[J].齐齐哈尔医学院学报,2007,28(3):315-316. 被引量:9
  • 3戴自英,张瑶年,李瑞.中国常用药品集[M].上海:上海交通大学出版社,2006.117.
  • 4IOM (Institute of Medicine). Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press, 2011.
  • 5Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm, 2009, 66(1): 82-98.
  • 6Matsumoto K1, Takesue Y, Ohmagari N, et al, Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. JInfect Chemother, 2013, 19(3): 365- 380.
  • 7Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J, 1979, 121(5):1193- 254.
  • 8Available at: http://www.tdmchina.org/portal.php?mod=view&aid= 373.
  • 9Available at: http://www.guidelines-registry,org.
  • 10Ye ZK, Chen K, Chen YL, et al. A Protocol of Chinese Practice Guideline for Therapeutic Drug Monitoring of Vancomycin. European Journal of Hospital Pharmacy. Accepted.

共引文献57

同被引文献56

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部